Pilot Study to Validate ex Vivo Expression of Specific Biomarkers of Human Resolutive Macrophages

NCT ID: NCT05106075

Last Updated: 2021-11-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-07

Study Completion Date

2024-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Human resolutive macrophages are essential immune cells in the resolution of inflammation. This particular type of macrophages remains poorly known and currently there are no biomarkers to identify them in vivo. Within UMR1098-RIGHT, specific biomarkers (secreted molecules and membrane receptors) of human resolutive macrophages (healthy volunteers) have been identified in vitro, but their existence in vivo remains an outstanding issue. An exploratory study (lack of data from the literature) will validate the ex vivo expression of these markers in samples of patients whose inflammation is not, or little, supported by the available therapies (NSAIDs, biotherapies, corticosteroids).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

macrophage inflammation inflammation resolution

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

patients are anonymized

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

biologic sample collection

Blood samples or gingival exsudat collection

Group Type EXPERIMENTAL

blood sample or joint fluid or gingival exudate

Intervention Type PROCEDURE

blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample or joint fluid or gingival exudate

blood sample collected by peripheral blood mobilization joint fluid collected by punction gingival exudate collected with paper strips

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age Limits (18-80 years)
* Information and non-opposition for participating in the study
* Patients suffering from periodontitis grade III ou IV
* Patients suffering from microcristalline arthritis
* patient with health insurance

Exclusion Criteria

* patient under corticotherapy
* pregnancy
* non-compliant patient
* patient with no health insurance
* patient in exclusion period from an other study
* legal incapacity
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU Besançon

Besançon, , France

Site Status RECRUITING

Dentist'S Office

Montbéliard, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas CHERRIER, MCU-PH

Role: CONTACT

Phone: +33(0)768207057

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Daniel Wendling

Role: primary

Laure Tisserand

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020/562

Identifier Type: -

Identifier Source: org_study_id